Genovefa A Papanicolaou1, Celalettin Ustun2, Jo-Anne H Young3, Min Chen4, Soyoung Kim5, Kwang Woo Ahn4,5, Krishna Komanduri6, Caroline Lindemans7, Jeffery J Auletta8, Marcie L Riches9. 1. Infectious Diseases Service, Memorial Sloan Kettering Cancer Center, New York, New York. 2. Rush University Division of Hematology, Oncology and Transplantation, Chicago, Illinois. 3. Department of Medicine, University of Minnesota Medical Center, Minneapolis. 4. Center for International Blood and Marrow Transplant Research, Department of Medicine. 5. Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee. 6. University of Miami, Florida. 7. Pediatric Blood and Marrow Transplantation Program, University Medical Center, Utrecht University, The Netherlands. 8. Blood and Marrow Transplant Program and Host Defense Program, Divisions of Hematology/Oncology/Bone Marrow Transplant and Infectious Diseases, Nationwide Children's Hospital, Columbus, Ohio. 9. Division of Hematology/Oncology, the University of North Carolina at Chapel Hill.
Abstract
BACKGROUND: We examined the impact of vancomycin-resistant Enterococcus (VRE) bloodstream infection (BSI) on outcomes of allogeneic hematopoietic cell transplantation (HCT) utilizing the Center for International Blood and Marrow Transplant Research database. METHODS: Adult and pediatric patients (N = 7128) who underwent first HCT for acute leukemia or myelodysplastic syndrome from 2008 through 2012 were analyzed as 3 groups-VRE BSI, non-VRE BSI, without BSI-according to BSI status at 100 days (D100) after allogeneic HCT. Multivariable models examined the effect of VRE BSI for overall survival (OS) and nonrelapse mortality (NRM) at 1 year. RESULTS: Of 7128 patients, 258 (3.2%) had VRE BSI, 2398 (33.6%) had non-VRE BSI, and 4472 (63%) had no BSI. The median time to VRE BSI and non-VRE BSI were D11 and D15, respectively. Compared with non-VRE BSI patients, VRE BSI patients were older, had advanced-stage acute leukemia, and received umbilical cord blood (UCB) allografts. In multivariable models, VRE BSI was associated with lower OS (relative risk [RR], 2.9;(99% confidence interval [CI], 2.2-3.7) and increased NRM (RR, 4.7; 99% CI, 3.6-6.2) (P < .0001) for both. Other predictors for worse OS and increased NRM were non-VRE BSI, older age, advanced disease stage, UCB allograft, - mismatch, comorbidity index ≥3, and cytomegalovirus seropositivity (P < .001 for all variables). CONCLUSIONS: VRE BSI is associated with lowest OS and highest NRM compared with patients without BSI or non-VRE BSI. Novel interventions that address the pathophysiology of VRE BSI have the potential of improving survival after HCT.
BACKGROUND: We examined the impact of vancomycin-resistant Enterococcus (VRE) bloodstream infection (BSI) on outcomes of allogeneic hematopoietic cell transplantation (HCT) utilizing the Center for International Blood and Marrow Transplant Research database. METHODS: Adult and pediatric patients (N = 7128) who underwent first HCT for acute leukemia or myelodysplastic syndrome from 2008 through 2012 were analyzed as 3 groups-VRE BSI, non-VRE BSI, without BSI-according to BSI status at 100 days (D100) after allogeneic HCT. Multivariable models examined the effect of VRE BSI for overall survival (OS) and nonrelapse mortality (NRM) at 1 year. RESULTS: Of 7128 patients, 258 (3.2%) had VRE BSI, 2398 (33.6%) had non-VRE BSI, and 4472 (63%) had no BSI. The median time to VRE BSI and non-VRE BSI were D11 and D15, respectively. Compared with non-VRE BSI patients, VRE BSI patients were older, had advanced-stage acute leukemia, and received umbilical cord blood (UCB) allografts. In multivariable models, VRE BSI was associated with lower OS (relative risk [RR], 2.9;(99% confidence interval [CI], 2.2-3.7) and increased NRM (RR, 4.7; 99% CI, 3.6-6.2) (P < .0001) for both. Other predictors for worse OS and increased NRM were non-VRE BSI, older age, advanced disease stage, UCB allograft, - mismatch, comorbidity index ≥3, and cytomegalovirus seropositivity (P < .001 for all variables). CONCLUSIONS: VRE BSI is associated with lowest OS and highest NRM compared with patients without BSI or non-VRE BSI. Novel interventions that address the pathophysiology of VRE BSI have the potential of improving survival after HCT.
Authors: Carles Ubeda; Ying Taur; Robert R Jenq; Michele J Equinda; Tammy Son; Miriam Samstein; Agnes Viale; Nicholas D Socci; Marcel R M van den Brink; Mini Kamboj; Eric G Pamer Journal: J Clin Invest Date: 2010-11-22 Impact factor: 14.808
Authors: Ying Taur; Robert R Jenq; Miguel-Angel Perales; Eric R Littmann; Sejal Morjaria; Lilan Ling; Daniel No; Asia Gobourne; Agnes Viale; Parastoo B Dahi; Doris M Ponce; Juliet N Barker; Sergio Giralt; Marcel van den Brink; Eric G Pamer Journal: Blood Date: 2014-06-17 Impact factor: 22.113
Authors: M Tavadze; L Rybicki; S Mossad; R Avery; M Yurch; B Pohlman; H Duong; R Dean; B Hill; S Andresen; R Hanna; N Majhail; E Copelan; B Bolwell; M Kalaycio; R Sobecks Journal: Bone Marrow Transplant Date: 2014-08-11 Impact factor: 5.483
Authors: Alexandra H Filipovich; Daniel Weisdorf; Steven Pavletic; Gerard Socie; John R Wingard; Stephanie J Lee; Paul Martin; Jason Chien; Donna Przepiorka; Daniel Couriel; Edward W Cowen; Patricia Dinndorf; Ann Farrell; Robert Hartzman; Jean Henslee-Downey; David Jacobsohn; George McDonald; Barbara Mittleman; J Douglas Rizzo; Michael Robinson; Mark Schubert; Kirk Schultz; Howard Shulman; Maria Turner; Georgia Vogelsang; Mary E D Flowers Journal: Biol Blood Marrow Transplant Date: 2005-12 Impact factor: 5.742
Authors: N G Almyroudis; A Fuller; A Jakubowski; K Sepkowitz; D Jaffe; T N Small; T E Kiehn; E Pamer; G A Papanicolaou Journal: Transpl Infect Dis Date: 2005-03 Impact factor: 2.228
Authors: R Avery; M Kalaycio; B Pohlman; R Sobecks; E Kuczkowski; S Andresen; S Mossad; J Shamp; J Curtis; J Kosar; K Sands; M Serafin; B Bolwell Journal: Bone Marrow Transplant Date: 2005-03 Impact factor: 5.483
Authors: Christopher E Dandoy; Soyoung Kim; Min Chen; Kwang Woo Ahn; Monica I Ardura; Valerie Brown; Saurabh Chhabra; Miguel Angel Diaz; Christopher Dvorak; Nosha Farhadfar; Aron Flagg; Siddartha Ganguly; Gregory A Hale; Shahrukh K Hashmi; Peiman Hematti; Rodrigo Martino; Taiga Nishihori; Roomi Nusrat; Richard F Olsson; Seth J Rotz; Anthony D Sung; Miguel-Angel Perales; Caroline A Lindemans; Krishna V Komanduri; Marcie L Riches Journal: JAMA Netw Open Date: 2020-01-03
Authors: German A Contreras; Jose M Munita; Shelby Simar; Courtney Luterbach; An Q Dinh; Kirsten Rydell; Pranoti V Sahasrabhojane; Rafael Rios; Lorena Diaz; Katherine Reyes; Marcus Zervos; Helina M Misikir; Gabriela Sanchez-Petitto; Catherine Liu; Yohei Doi; Lilian M Abbo; Luis Shimose; Harald Seifert; Carlota Gudiol; Fernanda Barberis; Claudia Pedroza; Samuel L Aitken; Samuel A Shelburne; David van Duin; Truc T Tran; Blake M Hanson; Cesar A Arias Journal: Open Forum Infect Dis Date: 2021-12-23 Impact factor: 4.423
Authors: Stephen M Maurer; Kathleen A Linder; Carol A Kauffman; Philip J McDonald; Jonathan Arcobello; Jon Velasco; Pranatharthi H Chandrasekar; Sanjay G Revankar; Marisa H Miceli Journal: Bone Marrow Transplant Date: 2022-09-23 Impact factor: 5.174